GlassScriptPhysician profile
Christopher Peluso
NPI 1649596701
$6,491.37
in general payments reported to CMS, 2019-2025
8 companies · $867 in 2025
The $867 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $363 · 2022: $3,136 · 2023: $1,290 · 2024: $835 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,487 · Honoraria: $500 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,486.89 |
| Honoraria | $500.00 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $3,549.07 | 2021-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Corium, LLC | $1,698.97 | 2021-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $539.02 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $422.40 | 2022-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $155.15 | 2021-2023 | Trintellix |
| Neos Therapeutics, LP | $53.87 | 2023-2025 | Cotempla Xr-Odt, Metadate Cd |
| Collegium Pharmaceutical, INC. | $48.70 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $24.19 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Peluso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.